Diarylureas and Diarylamides with Pyrrolo[2,3-d]pyrimidine Scaffold as Broad-Spectrum Anticancer Agents

DOI Web Site Web Site PubMed
  • El-Gamal Mohammed Ibrahim
    Center for Biomaterials, Korea Institute of Science and Technology Department of Biomolecular Science, University of Science and Technology Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura
  • Oh Chang-Hyun
    Center for Biomaterials, Korea Institute of Science and Technology Department of Biomolecular Science, University of Science and Technology

書誌事項

タイトル別名
  • Diarylureas and Diarylamides with Pyrrolo[2,3-<i>d</i>]pyrimidine Scaffold as Broad-Spectrum Anticancer Agents

この論文をさがす

抄録

A series of diarylureas and diarylamides possessing pyrrolo[2,3-d]pyrimidine scaffold was designed and synthesized. The in vitro antiproliferative activities of a selected group of the target compounds against NCI-60 cell line panel were tested and compared with Sorafenib and Imatinib as reference compounds. Most of the compounds showed strong and broad-spectrum antiproliferative activities. Compounds IVa, IVb, and IVd with benzamido moiety at position 4 of the pyrrolo[2,3-d]pyrimidine nucleus, para-disubstituted phenyl ring at N1-position of pyrrolo[2,3-d]pyrimidine scaffold, and urea linker showed strong and broad-spectrum anticancer results with high potencies and efficacies. In addition, the amide derivatives Vb and Vc demonstrated one-digit nanomolar IC50 values over two and one cell line(s), respectively. Amid all the target compounds, compound IVa demonstrated the best results in both one-dose and five-dose testing modes. It showed 109.18% mean % inhibition over the NCI-60 cancer cell line panel at 10 µM concentration, submicromolar 50% inhibitory concentration (IC50) values over eight cell lines of eight different cancer types, and high efficacy with total growth inhibition (TGI) and 50% lethal concentration (LC50) values less than 4.22 µM over three colon, ovarian, and prostate cancer cell lines. It showed superior potency and efficacy to Sorafenib and Imatinib over most of the tested cell lines.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ